Estudo de PIT565 em Malignidades de Células B Recidivantes e/ou Refratárias
Um estudo de fase I, aberto e multicêntrico de PIT565 em pacientes com neoplasias de células B recidivantes e/ou refratárias
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.
The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).
During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.
Different schedules and routes of administrations will be explored in the dose escalation groups.
The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Ghent, Bélgica, 9000
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100730
- Novartis Investigative Site
-
Shanghai, China, 200032
- Novartis Investigative Site
-
Tianjin, China, 300020
- Novartis Investigative Site
-
-
-
-
-
Singapore, Cingapura, 119074
- Novartis Investigative Site
-
Singapore, Cingapura, 169608
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espanha, 08035
- Novartis Investigative Site
-
Barcelona, Espanha, 08036
- Novartis Investigative Site
-
-
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- University Of Miami
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Medical Center
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- The University of Kansas Clinical Research Ctr
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Ctr
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health Sciences University
-
-
-
-
-
Créteil, França, 94010
- Novartis Investigative Site
-
Marseille, França, 13273
- Novartis Investigative Site
-
-
-
-
-
Tel Aviv, Israel, 6423906
- Novartis Investigative Site
-
-
-
-
RE
-
Reggio Emilia, RE, Itália, 42123
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japão, 2778577
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Male or female patients ≥18 years of age at the date of signing the informed consent form
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
NHL patient population
- Refractory or relapsed B-NHL
- Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
- Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan
ALL patient population
- Refractory or relapsed CD19-positive B-ALL
- Morphologic disease in the bone marrow (≥ 5% blasts)
Exclusion Criteria:
- History of severe hypersensitivity to any ingredient of the study treatment or its excipients
- Contraindication to tocilizumab
- History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
- Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
- Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
- Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
- Patients receiving systemic treatment with any immunosuppressive medication
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: PIT565 Group A (dose escalation part)
PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Experimental: PIT565 Group B (dose escalation part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Experimental: PIT565 Group A1 (dose expansion part)
PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Experimental: PIT565 Group A2 (dose expansion part)
PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Experimental: PIT565 Group B1 (dose expansion part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence and severity of Dose Limiting Toxicities (DLTs)
Prazo: 28 days or 35 days, depending on the dosing schedule
|
Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol. |
28 days or 35 days, depending on the dosing schedule
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: 21 months
|
Assessment of safety of study drug. |
21 months
|
|
Frequency of dose interruptions
Prazo: 21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Frequency of dose reductions
Prazo: 21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Dose intensities
Prazo: 21 months
|
Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
21 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Response Rate (ORR)
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Complete Response (CR) rate
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Best Overall Response (BOR)
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Duration Of Response (DOR)
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Overall Survival (OS)
Prazo: 33 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
33 months
|
|
Progression Free Survival (PFS)
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Event-free survival (EFS)
Prazo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Maximum concentration of PIT565 (Cmax)
Prazo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Area Under the Curve of PIT565 (AUC)
Prazo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Trough concentration of PIT565 (C trough)
Prazo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Prevalence of Anti-drug antibodies (ADA) at baseline
Prazo: Baseline
|
Assessment of anti-PIT565 antibodies in serum. |
Baseline
|
|
Incidence of Anti-drug antibodies (ADA) on treatment
Prazo: 21 months
|
Assessment of anti-PIT565 antibodies in serum. |
21 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Infecções
- Doenças Virais
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Infecções por vírus de DNA
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma
- Leucemia Linfóide
- Leucemia
- Infecções pelo vírus Epstein-Barr
- Infecções Herpesviridae
- Infecções por Vírus Tumorais
- Doenças hemic e linfáticas
- Linfoma de Células B
- Leucemia-Linfoma Linfoblástico de Células Precursoras
- Linfoma de Burkitt
- Linfoma Não-Hodgkin
Outros números de identificação do estudo
Outros números de identificação do estudo
- CPIT565A12101
- 2022-000367-45 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .